USSN: 10/720,431 Docket No.: 2352.001 Inventor(s): Shirasawa et al.

## **AMENDMENTS TO THE CLAIMS**

The following listing of claims will replace all prior versions and listings of claims in the application:

## **Listing of Claims:**

- 1. (Cancelled)
- 2. (Original) A method for alleviating tissue hypoxia, comprising administering to a subject in need thereof
- (1)  $\alpha$ -globin having the Titusville mutation,
- (2) a polynucleotide comprising a base sequence encoding an amino acid sequence of said  $\alpha$ -globin having the Titusville mutation, or
- (3) an expression vector comprising said polynucleotide, in an amount effective therefor.
- 3. (Original) A method for treating or preventing ischemic conditions, comprising administering to a subject in need thereof
- (1)  $\alpha$ -globin having the Titusville mutation,
- (2) a polynucleotide comprising a base sequence encoding an amino acid sequence of said  $\alpha$ -globin having the Titusville mutation, or
- (3) an expression vector comprising said polynucleotide, in an amount effective therefor.
- 4. (Original) The method according to claim 3, wherein the ischemic conditions are respiratory failure, ischemic diseases, ischemic heart diseases, myocardial infarction, angina, cerebral ischemia, obstructive arterial disorders, or obstructive arteriosclerosis.
- 5. (Original) A method for enhancing an oxygen metabolism in tissues, comprising administering to a subject in need thereof
- (1) α-globin having the Titusville mutation,
- (2) a polynucleotide comprising a base sequence encoding an amino acid sequence of said  $\alpha$ -globin having the Titusville mutation, or
- (3) an expression vector comprising said polynucleotide, in an amount effective therefor.

USSN: 10/720,431 Docket No.: 2352.001 Inventor(s): Shirasawa et al.

- 6. (Original) The method according to claim 5, wherein the oxygen metabolism is an oxidative enzymatic activity.
- 7. (Amended) A method for modificating of modifying a tissue, comprising administering to a subject in need thereof
- (1)  $\alpha$ -globin having the Titusville mutation,
- (2) a polynucleotide comprising a base sequence encoding an amino acid sequence of said  $\alpha$ -globin having the Titusville mutation, or
- (3) an expression vector comprising said polynucleotide, in an amount effective therefor.
- 8. (Original) The method according to claim 7, wherein the tissue is muscles, heart, nerves, or skin.
- 9. (Original) A method for enhancing exercise capacity, comprising administering to a subject in need thereof
- (1)  $\alpha$ -globin having the Titusville mutation,
- (2) a polynucleotide comprising a base sequence encoding an amino acid sequence of said  $\alpha$ -globin having the Titusville mutation, or
- (3) an expression vector comprising said polynucleotide in an amount effective therefor.
- 10. (Original) The method according to claim 9, wherein the exercise capacity is running capacity.
- 11. (Original) A method for treating or preventing cerebrovascular dementia, comprising administering to a subject in need thereof
- (1)  $\alpha$ -globin having the Titusville mutation,
- (2) a polynucleotide comprising a base sequence encoding an amino acid sequence of said  $\alpha$ -globin having the Titusville mutation, or
- (3) an expression vector comprising said polynucleotide, in an amount effective therefor.

USSN: 10/720,431 Docket No.: 2352.001 Inventor(s): Shirasawa et al.

- 12. (Cancelled)
- 13. (Cancelled)